Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Abbott Laboratories (ABT - Analyst Report) recently announced that it is collaborating with Astellas Pharma Global Development for a phase III study being conducted with ASP0113 (TransVax). TransVax, a vaccine in-licensed by Astellas from Vical Inc. (VICL - Snapshot Report), is being developed for the prevention of cytomegalovirus (CMV) reactivation in transplant patients.

Under the collaboration, patients will be monitored for CMV viral load using Abbott Labs’ RealTime CMV assay, which is performed on the Abbott m2000 System. This will help evaluate the vaccine’s efficacy.

CMV, which infects 50% of all adults by the time they reach age 40, is the most common viral infection in transplant recipients.

Another company that is working on the development of a CMV infection treatment is ViroPharma Inc. . ViroPharma is currently conducting a phase II program to evaluate maribavir for the treatment of CMV infections in transplant recipients.

Maribavir will be studied in two independent phase II trials that will be conducted in patients who have asymptomatic CMV and patients who have failed therapy with other anti-CMV agents.

Abbott Labs’ partnership with Astellas is its fourth collaboration with a large pharma company in the last one year. Other agreements include Abbott Labs’ collaborations with Pfizer (PFE - Analyst Report), Merck (MRK - Analyst Report) and GlaxoSmithKline (GSK - Analyst Report) for the development of companion diagnostic tests that can be used to select patients suitable for certain oncology products.

Neutral on Abbott Labs

We currently have a Neutral recommendation on Abbott Labs, which carries a Zacks #3 Rank (short-term Hold rating). Abbott Labs remains on track to split into two separate publicly traded companies by the end of 2012.

While one company will deal in diversified medical products, the other (AbbVie) will focus on research-based pharmaceuticals. We are positive on the split which should allow the two separate entities to perform in a more focused manner. Humira continues to perform well and this should reduce concerns regarding AbbVie’s growth prospects.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
KNIGHTSBRIDG VLCCF 14.32 +14.19%
E*TRADE FINA ETFC 22.55 +4.88%
QUESTCOR PHA QCOR 83.22 +3.93%
BNC BANCORP BNCN 17.81 +2.77%
LAKE SHORE G LSG 0.79 +2.46%